[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438018":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":34,"studyPopulation":23,"armGroups":35,"interventions":48,"overallOfficials":56,"centralContacts":60,"locations":69,"responsibleParty":86,"collaborators":23,"id":88,"slug":23,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":23,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":23,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":71,"whyStopped":23,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Baker Heart and Diabetes Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Change in exercise capacity","Cardio pulmonary fitness (peak oxygen uptake (VO2 peak)) from baseline to follow up.","Over a period of 24 months",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"New onset heart failure","Symptoms and signs of heart failure (Framingham criteria)",{"measure":18,"description":19,"timeFrame":12},"Change in maximal isometric grip strength","Strength (kg) measured by electronic dynamometer",{"measure":21,"description":22,"timeFrame":12},"Change on quality of life","Change in score on Health related quality of life: Assessment of quality of life 8 Dimension.\n\nMinimum value 1, Maximum value 4. Higher values indicate worse outcome.",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":27,"primaryPurpose":28,"observationalModel":23,"timePerspective":23,"maskingInfo":29},"RANDOMIZED","PARALLEL","Randomization to CC-DMP or usual care","SCREENING",{"masking":30,"maskingDescription":31,"whoMasked":32},"SINGLE","Outcomes assessor will receive study data based on pooled de identified dataset.",[33],"OUTCOMES_ASSESSOR","Participants enrolled in this study will be randomized to a cardio-COVID disease management plan (CC-DMP) that involves the use of VO2 testing and surveillance imaging to detect reduced functional capacity and subclinical left ventricular dysfunction (LVD), clinical review to ensure optimal risk factor control and cardio-protection and exercise intervention. The program will be delivered over a period of 24 months.\n\nThe outcome from this study will show that subclinical LVD is common among COVID-19 survivors, and a CC-DMP is feasible in reducing HF risk factors in this sub group of survivors.",[36,42],{"label":37,"type":38,"description":39,"interventionNames":40},"Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)","EXPERIMENTAL","1. Optimization of pharmacotherapy:\n\n   This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.\n2. Exercise intervention: Individualized training program will be provided by an exercise physiologist",[41],"Other: Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)",{"label":43,"type":44,"description":45,"interventionNames":46},"Usual care","ACTIVE_COMPARATOR","All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).",[47],"Other: Usual care",[49,53],{"type":6,"name":50,"description":51,"armGroupLabels":52,"otherNames":23},"Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)","A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.",[37],{"type":6,"name":43,"description":54,"armGroupLabels":55,"otherNames":23},"This will be provided by participants' usual healthcare professional(s).",[43],[57],{"name":58,"affiliation":5,"role":59},"Thomas H Marwick, MD,PhD,MPH","PRINCIPAL_INVESTIGATOR",[61,66],{"name":62,"role":63,"phone":64,"phoneExt":23,"email":65},"Joel Smith, MSc","CONTACT","+61385321964","joel.smith@baker.edu.au",{"name":58,"role":63,"phone":67,"phoneExt":23,"email":68},"+61385321550","tom.marwick@baker.edu.au",[70],{"facility":5,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"RECRUITING","Melbourne","Victoria","3004","Australia","AU",{"type":78,"coordinates":79},"Point",[80,81],144.96332,-37.814,{"lat":81,"lon":80},[84],{"name":85,"role":63,"phone":67,"phoneExt":23,"email":68},"Thomas Marwick",{"type":87,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100438018",false,"NCT04983823","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure","Inclusion Criteria:\n\n1. History of COVID-19 infection\n2. Live within a geographically accessible area for follow-up\n\nExclusion Criteria:\n\n1. Valvular stenosis or regurgitation of \\>moderate severity\n2. History of previous heart failure (baseline New York Heart Association (NYHA) classification \\>2)\n3. Inability to acquire interpretable images (identified from baseline echo)\n4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors\n5. Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial\n6. Already taking both angiotensin converting enzyme inhibitors\u002F angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.\n7. Mobility impairment that would impact participants' ability to perform exercise\n8. Unable to provide written informed consent to participate in this study",true,"ALL","50 Years","85 Years",{"count":99,"type":100},820,"ESTIMATED","INTERVENTIONAL",[103],"NA","This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \\>50 years old.\n\nThe overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.",[106],"Heart Failure",[108,109],"Heart failure","COVID","2025-09-30",{"date":112,"type":113},"2025-10-03","ACTUAL",{"date":115,"type":113},"2021-11-18",{"date":117,"type":100},"2025-12-30",{"name":5,"class":6},1]